



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: January 06, 2023

To
The Manager
Department of Corporate Services
BSE Ltd.
Dalal Street, Fort
Mumbai - 400 001

Sub. - : Reg. 33 - Unaudited financial results for the Quarter and six months ended 30th September 2022

Ref. - : Scrip Code - 524414

Dear Sir / Madam,

The Board of Directors at their Meeting held on November 07, 2022, had approved the Un-audited financial results for the Quarter and Six months ended 30th September 2022. As per Regulation 33 of Listing Regulations, the Financial Results and Limited Review Report are enclosed herewith for your records.

As BSE's query the results are being re-submitted again. The figures of the Profit and Loss and Balance Sheet submitted are unchanged from the ones submitted earlier. The presentation of the Financials is as requested in BSE's email for the same.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

For Norris Medicines Limited

Vimal D. Shah
Managing Director

Encl: As above

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrisspharma.com. Website: www.norrisspharma.com

CIN : L24230GJ1990PLC086581

Rs. In Lakhs

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2022

Sl. No.	Particulars	QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	(a) Revenue from Operations	302.78	95.31	219.91	398.09	709.24	943.84
	(b) Other Income	0.00	0.00	0.00	0.00	1.65	2.58
	Total Income From Operations (Net)	302.78	95.31	219.91	398.09	710.89	946.42
2	Expenses						
	a. Cost of Materials Consumed	216.92	35.77	129.86	252.69	239.72	356.62
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	-41.64	-16.63	-6.47	-58.27	203.46	204.04
	c. Employee Benefit Expenses	60.38	44.14	68.71	104.52	129.76	233.00
	d. Finance Costs	64.80	9.28	49.85	74.07	92.32	148.15
	e. Depreciation and Amortisation Expense	15.14	15.14	16.15	30.28	32.31	65.69
	f. Other expenditure	43.49	51.53	40.66	95.02	97.66	157.37
	Total Expenses	359.09	139.23	298.77	498.32	795.23	1,164.87
3	Profit/ Loss before Tax (1-2)	-56.31	-43.92	-78.85	-100.23	-84.34	-218.45
4	Tax Expense						
	a: Current Tax	0.00	0.00	0.00	0.00	0.00	-
	b: Deferred Tax	0.00	0.00	0.00	0.00	0.00	107.90
5	Profit / Loss after Tax	-56.31	-43.92	-78.85	-100.23	-84.34	-326.35
6	Other Comprehensive Income						
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	-
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	-
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	-
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	-
7	Total Comprehensive Income for the period	-56.31	-43.92	-78.85	-100.23	-84.34	-326.35
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.56	-0.44	-0.79	-1.00	-0.84	-3.26



STATEMENT OF ASSETS AND LIABILITIES
30.09.2022 31.03.2022
Un audited (Audited)

A . ASSETS		
1. Non Current Assets		
a) Property, Plant & Equipment	676.93	706.95
b) Capital Work in Progress		
c) Investment Property		
d) Financial Assets		
i) Investments	0.94	0.94
ii) Loans	-0.20	0.38
iii) Others	39.79	40.81
e) Non Current Tax Assets (Net)	160.85	160.85
f) Other Non Current Assets	81.88	81.91
TOTAL NON CURRENT ASSETS	960.18	991.83
2. Current Assets		
a) Inventories	294.81	242.09
b) Financial Assets		
i) Trade Receivables	154.29	109.24
ii) Cash and Cash Equivalents	1.86	1.86
iii)Bank Balance other than"b" above.		
iv)Loans		
v) Others	75.89	74.06
TOTAL CURRENT ASSETS	526.85	427.25
TOTAL ASSETS	1487.03	1419.08
B. EQUITY & LIABILITIES		
1) Equity		
a) Equity Share Capital	992.58	992.58
b) Other Equity	-2162.18	-2,061.95
Total Equity	-1169.61	-1069.378947
2) Non Current Liabilities		
a) Financial Liabilities - Borrowings	1854.02	1,810.09
b)Provisions		
c) Deferred Tax Laibilities (Net)		
d) Non Current Tax Liabilities (Net)		
Total Non - Current Liabilities	1854.02	1810.09
3) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	296.45	297.62
ii) Trade payables	192.34	132.52
iii) Other financial liabilities	42.28	31.71
b) Other Current Liabilities	0.00	-
c) Provisions	271.55	216.51
Total Current Liabilities	678.37	-
TOTAL EQUITY AND LIABILITIES	1362.78	740.71



Notes:

1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 07.11.2022. The above results have been subjected to Limited Review by the Statutory Auditors of the company .
of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and
3) The Company is having one segment only and therefore Segmental Reporting is not applicable.

4) There are no exceptional/ extraordinary items during the quarter ended 30.09.2022.

5) The figures for the three months ended 30.09.2022 and 30.06.2022 are the balancing figures between the audited figures of the full financial years and the published year to date figures upto the end of six months period of the relevant year , which are subjected to

6) The Company has been impleaded as a party in matter pertaining to the year 2001 and the Hon' ble Special Judge of the Maharashtra Protection of Interest of Depositors (in Financial Establishments) Act, 1999 and the Additional Sessions Judge City Civil and Sessions Court, Mumbai has held the company liable jointly with the erstwhile Diector to pay the amount in Miscellaneous Application no. 481/2004 in Special Case no. 3 of 2003. The Company has filed an appeal against the said order dated 14.11.2019 before the High Court of Mumbai, under Criminal Appeal no. 89 of 2020.

7) Due to the outbreak of Covid 19 pandemic , globally and in India, the company has made an initial assessment of the likely adverse impact on economic environment in general and financial risk on account of Covid 19. The Company is in the business of Pharmaceutical manufacturing which is notified as essential service by the Ministry of Home Affairs, Government of India. The operations of the company were mildly impacted due to the mobility of labour and also the constraints of logistics during the initial phase of the lock down.

The Management has at the time of approving the financial statements, assessed the potential impact of Covid 19 on the Company.

Barring any future Covid 19 related escalation based on the current assessment the Management is of the view that the impact of Covid 19 on the operations of the Company and the carrying value of its assets and liabilities is not likely to be material.

For Norris Medicines Limited


Vimal D Shah
Managing Director



Date: 07.11.2022
Place: Ankleshwar

NORRIS MEDICINES LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 30th September 2022

		30.09.2022	31.03.2022
		Rs.Lakhs	Rs.Lakhs
(A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit/Loss before tax and extraordinary items	100.23	326.35
	Adjustments for :		
	Depreciation & Amortisation	30.28	65.69
	Deferred Tax Liability	-	107.90
	Interest Income	-	1.16
	Interest Paid	74.07	148.15
	Profit/Loss on Investment in bonds	-	-
	Profit/Loss on sale of Fixed Assets	-	-
	Other Non Operating Income	-	-
	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	4.13	5.77
	Adjustments for Changes in Working Capital		
	Increase/Decrease in Trade Debtors	45.04	69.60
	Increase/Decrease in Inventories	52.72	268.15
	Increase/Decrease in Loans & Advances	1.84	58.10
	Trade Payables and Other Liabilities	124.25	491.03
	Net cash from operations before taxation	24.65	95.18
	Tax Paid	-	-
	CASH FLOW BEFORE EXTRA ORDINARY ITEM	24.65	95.18
	Extra Ordinary Item	-	-
	NET CASH FROM OPERATING ACTIVITIES	28.77	100.94
(B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	0.27	5.54
	Sale of Fixed Assets	-	-
	Investments Made during the year	-	-
	Long Term Advances	1.63	4.51
	Receipt from Investment	-	-
	Interest Income	-	1.16
	Dividend Received	-	-
	Profit/Loss on sale of bonds	-	-
	Net Cash used in Investing Activities (B)	1.37	8.89



(C)	CASH FLOW FROM FINANCING ACTIVITIES:-		
	Share Capital	-	-
	Borrowings	43.93	257.78
	Interest paid	- 74.07	- 148.15
	Net Cash Used in Financing Activities (C)	- 30.15	109.63
	Net Increase/Decrease in Cash and Cash Equivalents (A+B+C)	- 0.01	- 0.21
		-	-
	Cash and Cash equivalents - Opening balance	1.86	2.07
	Cash and cash equivalents - Closing balance	1.86	1.86
		0.01	0.21

Component of Cash & Cash Equivalents:
Cash on hand

Date: 07.11.2022
Place: Ankleshwar

FOR NORRIS MEDICINES LIMITED



Vimal D Shah
Managing Director





H.N. JADAV & CO.
CHARTERED ACCOUNTANTS

CA Harishchadra N. Jadav
B. Com, FCA, DISA (ICAI)
Mobile : 98241 25540
harishnjadav@yahoo.com
harishnjadav@gmail.com

C-24, GROUND FLOOR, SARDAR PATEL MUNICIPAL MARKET, SHAKTINATH, BHARUCH- 392 001.

Limited Review Report

To
The Board of Directors
Norris Medicines Limited
Ankleshwar

We have reviewed the accompanying statement of Standalone unaudited financial results of **NORRIS MEDICINES LIMITED** ("the company") for the quarter ended **30th Sep, 2022**, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement is the responsibility of the Company's Management and has been approved by the Board of directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standards 34, "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of Companies Act 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





H.N. JADAV & CO.
CHARTERED ACCOUNTANTS

CA Harishchandra N. Jadav
B. Com, FCA, DISA (ICAI)
Mobile : 98241 25540
harishnjadav@yahoo.com
harishnjadav@gmail.com

C-24, GROUND FLOOR, SARDAR PATEL MUNICIPAL MARKET, SHAKTINATH, BHARUCH- 392 001.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards , i.e. Indian Accounting Standard ("Ind AS") and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bharuch
Date: 07/11/2022

C-24, Ground Floor,
Sardar Patel Municipal Market,
Shaktinath, Bharuch- 392001
Gujarat

For, H. N. JADAV & Co.
Chartered Accountants

CA HARISHCHANDRA JADAV

Proprietor

M. No. 040525

Firm Reg. No. 103801W

UDIN: 22040525BCMCBC9285

